FDA accepted NDA for zidesamtinib for the treatment of TKI pre-treated patients with advanced ROS1-positive NSCLC; PDUFA target action date of September ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...
Encouraging preliminary activity observed across diverse set of advanced ALK-positive solid tumors Global enrollment ongoing for adult and adolescent patients with advanced ALK-positive solid tumors ...
About five percent of lung adenocarcinomas, one of the most common forms of lung cancer, are driven by a faulty fusion of two genes, EML4 and ALK. This fusion results in different variants, and until ...
CAMBRIDGE, Mass., July 21, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase ...
Lymphomas belong to the group of malignant diseases of the immune system and mainly affect the organs of the lymphatic system. Anaplastic large cell lymphoma (ALCL) belongs to the subgroup of ...
Panelists discuss how they will explore optimizing care for patients with ALK-positive non-small cell lung cancer (ALK+ NSCLC) through treatment selection, sequencing strategies, and interpretation of ...
Thoracic medical oncologists and early drug development specialists at Memorial Sloan Kettering Cancer Center (MSK) continue to investigate new ways to improve outcomes for this patient population.
ALK Tyrosine Kinase Inhibitors Induced Weight Gain: More Refined Definition of Weight Gain, Glucagon-Like Peptide-1 Agonist Treatment, and Therapeutic Drug Monitoring of ALK+ Non–Small Cell Lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback